Business Context and Reporting Period
This Form 8-K was filed by OncoCyte Corporation (noted as Insight Molecular Diagnostics Inc. in metadata) on January 22, 2016. The report details the entry into a Material Definitive Agreement with The Wistar Institute of Anatomy and Biology ("Wistar").
Key Financial Metrics and Obligations
The filing outlines specific financial obligations associated with the new License Agreement rather than reporting historical financial performance metrics such as revenue or cash flow.
- Initial Payment: An initial license fee has been paid to Wistar.
- Royalties: OncoCyte will pay royalties on net sales of Licensed Products ranging from 3% to 5%, dependent on cumulative net sales.
- Royalty Reduction: If third-party royalties are required, payments to Wistar may be reduced by that amount, capped at a 50% reduction.
- Minimum Annual Royalty: A minimum annual royalty is required for each subsequent year, credited against total royalties due.
- Maintenance Fee: An annual license maintenance fee is required unless sales of at least one Licensed Product commence by January 1, 2018.
- Milestone Payments: Payments are due upon the occurrence of specific development and commercialization milestones.
- Cost Reimbursement: OncoCyte must pay all past or ongoing costs incurred by Wistar for prosecuting licensed patents, including government and attorney fees.
- Sublicensing Income: A portion of non-royalty sublicensing income must be paid to Wistar.
Material Changes and Agreement Terms
The primary material change is the execution of an exclusive, worldwide license for patents and technical information related to molecular diagnostics for lung cancer. Key terms include:
- Licensed Field: Confirmatory, companion, and recurrence diagnostics for lung cancer using whole blood, fractionated blood, plasma, serum, or other biological samples.
- Sublicensing: OncoCyte may grant sublicenses subject to Wistar's approval (not to be unreasonably withheld) if OncoCyte is not selling a Licensed Product.
- Term: Royalty obligations terminate on a product-by-product and country-by-country basis upon the later of patent expiration or the 10th anniversary of the first commercial sale.
- Commercialization Obligation: OncoCyte must use commercially reasonable efforts to develop and commercialize products. Failure to commence sales by a specified date allows for up to three one-year extensions upon payment of a designated fee.
Guidance, Risks, and Contingencies
The filing includes standard forward-looking statements and specific risks associated with the agreement:
- Indemnification: OncoCyte must indemnify Wistar against liabilities arising from the agreement, product liability, IP infringement claims, and clinical trials, excluding Wistar's gross negligence or willful misconduct.
- Termination Risks: Wistar may terminate the agreement for non-payment, material breach, bankruptcy, dissolution, challenges to patent validity, or failure to meet diligence obligations. OncoCyte may terminate for Wistar's material breach or, after the second anniversary, without cause upon notice.
- Wistar Retained Rights: Wistar retains rights for internal research and non-commercial academic use. Wistar may also develop or license products in the field if OncoCyte fails to actively develop them.
Investor Verification Checklist
- Verify the exact amount of the initial license fee paid, as the filing states it was paid but does not disclose the figure.
- Confirm the specific "designated fee" required for the one-year commercialization deadline extensions.
- Review the full text of the License Agreement (to be filed as an exhibit to the Form 10-K) for complete terms regarding the definition of "net sales" and specific milestone triggers.
- Assess the company's current cash position against the immediate obligations of the maintenance fee and patent prosecution cost reimbursements.
- Monitor the January 1, 2018 deadline for the commencement of sales to avoid ongoing maintenance fees.